Mesenchymal Stem Cells for the Treatment of Patients with COVID-19 Severe/Critical Category: A Review

COVID-19 has developed into a public health emergency of international concern and is a major threat to global health. Several studies have been conducted with the aim of dampening the inflammatory response in COVID-19 patients. To dampen the cytokine storm, some therapies immunotargeting IL-1, IL-2, IL-6, and TNFα are being evaluated and one of the promising immune modulators is mesenchymal stem cells (MSCs). MSCs have the beneficial effect of preventing or attenuating cytokine storms by secreting potent anti-inflammatory factors and addressing the severity of the COVID-19 infection.

This study examines the mesenchymal stem cells for the treatment of patients with COVID-19 severe/critical category. This literature review outlines the therapeutic effectiveness of MSCs in the treatment of COVID-19 in the critically ill patient category.

Several research showed that the administration of MSC therapy in COVID-19 patients has significant clinical improvement results, normalized the vital signs of patients, reduced the severity and reduced mortality. In addition, overall treatment with MCS did not cause side effects.